Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $658K fell 17.9% year over year, behind the -16.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.

Context

  • Depreciation & amortization amounted to 4.5% of revenue in FY2025, up 1.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.9% toward the trailing-twelve-month pace of -16.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$658K-3.5% QoQ
Last fiscal yearDec 2025
$3.03M-14.6% YoY
LTMMar 2026
$2.88M-16.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.9%——
1 year-14.6%——
3-year CAGR+25.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
3.03M USD
Year-over-year change
-14.6%
4-year CAGR
+26.2%

Depreciation & Amortization vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.2% is the 8th highest of 10, against a peer median of +0.0%.
  • Depreciation & amortization amounts to 6.4% of revenue for ARCT, versus a peer median of 18.2%.
ARCT Competitors
Depreciation & Amortization for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VALNValneva SELTM Mar 2026€25.21M EUR+138.6%+1.1%16.1%
NVAXNovavax, Inc.LTM Mar 2026$22.34M USD-50.0%-1.7%3.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M USD+41.3%+46.1%27.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$10.18M USD+0.4%+20.7%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$2.99M USD-3.9%-18.4%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M USD-16.2%+25.6%6.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$1.07M USD-21.3%-36.6%0.6%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026$475K USD+28.7%+0.3%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K USD+0.0%+17.0%—
Peer median (excluding ARCT) —+0.0%+0.7%18.2%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
Deferred Income Tax00000
Stock-Based Compensation28.92M30.61M34.65M37.99M25.41M
Change in Working Capital32.63M(12.56M)7.38M(20.81M)(39.2M)
Accounts Receivables(1.24M)603K(29.3M)28.09M(1.59M)
Inventory00000
Accounts Payables(769K)(3.11M)(2.24M)1.92M(2.96M)
Other Working Capital34.64M(10.05M)38.92M(50.81M)(34.65M)
Other Non-Cash Items5.9M3.06M(33.36M)471K2.28M
Operating Cash Flow(135.04M)31.99M(18.1M)(59.75M)(74.27M)
Capital Expenditures(3.41M)(7.73M)(2.9M)(648K)(230K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(3.41M)(7.73M)(2.9M)(648K)(230K)
Debt Repayment46.6M(5M)(27.36M)00
Common Stock Issued515K411K609K682K13.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities902K1.73M2.67M4.74M0
Financing Cash Flow48.02M(2.86M)(24.09M)5.42M13.38M
Effect of Forex Changes00000
Net Change in Cash(90.43M)21.41M(45.09M)(54.98M)(61.12M)
Free Cash Flow(138.45M)24.27M(21M)(60.4M)(74.27M)

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.